Toni Choueiri, MD, on Updated Follow-up Data in RCC at 2021 ASCO
Choueiri detailed combination treatments with follow-up data presented at the 2021 ASCO Annual Meeting.
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork® about trials of combination therapies that had updated data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Transcription:
There were some studies that were not presented for the first time, but more analysis. So, KEYNOTE-426 [NCT02853331], for example, that [led to the approval of the combination] of pembrolizumab [Keytruda] and axitinib [Inlyta] now has a long median follow-up.
I think one of the issues with these VEGF/IO [immunotherapy] combinations [is that] they never have the same follow up as the IO/IO combinations like nivolumab [Opdivo]/ipilimumab [Yervoy]. Now, pembrolizumab/axitinib has more follow up [and it will] be interesting to look at the data in detail. There are data also for a newer combination of pembrolizumab/lenvatinib [Lenvima] that was presented a couple of months ago. There are data now about quality of life, we know this patient[-reported outcome].
There’s a lot of good stuff to be presented and I hope folks will follow all the data virtually that is coming in renal cell cancer, but also in [genitourinary] cancer in general.
